Targeting Glioblastoma Cell State Plasticity for Enhanced Therapeutic Efficacy

Area of Science:

• Neuro-oncology
• Cancer biology
• Genomics

Background:

• Glioblastoma (GBM) is a deadly brain cancer with poor treatment outcomes.
• Intratumoral heterogeneity and mesenchymal-like (MES-L) phenotypes contribute to treatment failure.

Purpose of the Study:

• To characterize drug-mediated transcriptomic changes in glioblastoma stem cells (GSCs).
• To investigate the role of cell state plasticity in therapeutic response.
• To explore novel combination drug strategies for GBM.

Main Methods:

• Screening of diverse drugs on patient-derived GSCs.
• Single-cell transcriptomic analysis to assess cellular state dynamics.
• Utilizing barcoded analysis in an ex vivo glioblastoma cerebral organoid (GLICO) model.

Main Results:

• Anti-tumor drugs induce reversible, drug-specific changes in GSC states (mesenchymal-like and astrocytic-like).
• Histone deacetylase inhibitor panobinostat's efficacy depends on FOSL1 modulation.
• Combining MES-L enhancing and suppressing agents increases anti-glioma activity ('state-selective lethality').

Conclusions:

• Cell state plasticity is crucial for GSC response to anti-cancer drugs.
• Targeting cell state transitions offers a promising therapeutic avenue for GBM.
• Novel combination drug strategies can overcome treatment resistance in glioblastoma.